Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Verona Pharma (Nasdaq: VRNA) will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 2:00 PM ET. A webcast of the presentation will be available on the Company's website.

Verona Pharma focuses on innovative therapies for respiratory diseases. Its leading product candidate, ensifentrine, aims to combine bronchodilator and anti-inflammatory properties for COPD treatment. After successfully meeting primary endpoints in clinical trials, ensifentrine shows promise for COPD maintenance and potential applications in other respiratory diseases.

LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the H.C. Wainwright 24^th Annual Global Investment Conference on Monday, September 12, 2022 at 2:00 PM ET / 7:00 PM BST.

A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.

For further information please contact:

Verona Pharma plc	US Tel: +1-833-417-0262 UK Tel: +44 (0)203 283 4200
Victoria Stewart, Director of Investor Relations and Communications	info@veronapharma.com
Argot Partners (US Investor Enquiries)	Tel: +1-212-600-1902 verona@argotpartners.com
Kimberly Minarovich / Carrie McKim
Optimum Strategic Communications (International Media and European Investor Enquiries)	Tel: +44 (0)203 950 9144 verona@optimumcomms.com
Mary Clark / Rebecca Noonan / Zoe Bolt

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ensifentrine met the primary endpoint in ENHANCE-2 demonstrating a statistically significant and clinically meaningful improvement in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in the ENHANCE-2 trial. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com

FAQ

When will Verona Pharma present at the H.C. Wainwright Global Investment Conference?

Verona Pharma will present on September 12, 2022, at 2:00 PM ET.

What is the significance of ensifentrine for Verona Pharma?

Ensifentrine has the potential to be the first therapy combining bronchodilator and anti-inflammatory activities for respiratory diseases.

What clinical results has ensifentrine achieved?

Ensifentrine met primary endpoints in the ENHANCE-2 trial, showing significant improvements in lung function and reduced COPD exacerbation rates.

Where can I find the webcast of Verona Pharma's presentation?

The webcast will be available on the Events and Presentations link on Verona Pharma's Investors page.

What other diseases could ensifentrine potentially treat?

In addition to COPD, ensifentrine may have applications in cystic fibrosis and asthma.